Michael R. Burgess

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

Michael R. Burgess, Brian J. Skaggs, Neil P. Shah et al. · Proceedings of the National Academy of Sciences · 2005 · 311 citations · Full text

Drug Target, Mixed-phenotype Acute Leukemia, Molecular Biology +18

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Luciano J. Costa, Sandy W. Wong, Arancha Bermúdez et al. · Blood · 2019 · 158 citations

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

Brian J. Skaggs, M. Gorre, Michael R. Burgess et al. · Proceedings of the National Academy of Sciences · 2006 · 145 citations · Full text

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia

Nina Fenouille, Christopher F. Bassil, Issam Ben‐Sahra et al. · Nature Medicine · 2017 · 118 citations · Full text

Hematological Malignancy, Signal Transduction, Biochemistry +10

Preclinical efficacy of MEK inhibition in Nras-mutant AML

Michael R. Burgess, Eugene Hwang, Ari J. Firestone et al. · Blood · 2014 · 103 citations · Full text